Physiological study of NGAL and Cystatin C in chronic and acute kidney disease patients

Abstract

Kidney disease is an important global health concern, affecting ~15% of the global population and typically associated with systemic disorders (e.g., diabetes). Increased incidence of kidney diseases and their progression to critical stages are facing many nations across the globe. The current study was performed with 65 male patients (20 with Acute kidney disease and 45 with chronic kidney disease, their mean age (44.38±14.59) years, who have visited the physician's consultancies and the kidney disease unit at Al-Sadder Teaching hospital in Al-najaf, Iraq, and 25 persons as a healthy control group their mean age (48.68±16.37) years, They were all Males with no prior medical history and no indications or symptoms of renal disease, diabetes, anemia, hypertension, thyroid illness, dyslipidemia, or obesity . The study was conducted from September 2021 to May 2022. Biomarker appropriate for kidney failure monitoring should have narrow biological variability Such as NGAL and Cystatin C Were biomarkers of tubular epithelial cells injury and pathogenesis of KD progression, it was predicted to be reflecting disease activity and kidney function. In this study, serum NGAL and Cystatin C levels were measured in patients and healthy groups.